Beam Therapeutics Inc.
BEAM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $63,518 | $377,709 | $60,920 | $51,844 |
| % Growth | -83.2% | 520% | 17.5% | – |
| Cost of Goods Sold | $367,561 | $0 | $311,594 | $232,134 |
| Gross Profit | -$304,043 | $377,709 | -$250,674 | -$180,290 |
| % Margin | -478.7% | 100% | -411.5% | -347.8% |
| R&D Expenses | $367,561 | $437,381 | $311,594 | $387,087 |
| G&A Expenses | $111,525 | $116,813 | $87,805 | $57,222 |
| SG&A Expenses | $111,525 | $116,813 | $87,805 | $57,222 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$367,561 | $0 | -$311,594 | -$232,134 |
| Operating Expenses | $111,525 | $554,194 | $87,805 | $212,175 |
| Operating Income | -$415,568 | -$176,485 | -$338,479 | -$392,465 |
| % Margin | -654.3% | -46.7% | -555.6% | -757% |
| Other Income/Exp. Net | $38,865 | $45,324 | $52,801 | $21,827 |
| Pre-Tax Income | -$376,703 | -$131,161 | -$285,678 | -$370,638 |
| Tax Expense | $39 | $1,366 | $3,410 | $0 |
| Net Income | -$376,742 | -$132,527 | -$289,088 | -$370,638 |
| % Margin | -593.1% | -35.1% | -474.5% | -714.9% |
| EPS | -4.58 | -1.72 | -4.13 | -5.77 |
| % Growth | -166.3% | 58.4% | 28.4% | – |
| EPS Diluted | -4.58 | -1.72 | -4.13 | -5.77 |
| Weighted Avg Shares Out | 82,313 | 77,152 | 70,015 | 64,228 |
| Weighted Avg Shares Out Dil | 82,313 | 77,152 | 70,015 | 64,228 |
| Supplemental Information | – | – | – | – |
| Interest Income | $49,094 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $21,925 | $29,531 | $14,147 | $7,451 |
| EBITDA | -$393,643 | -$146,954 | -$324,332 | -$230,061 |
| % Margin | -619.7% | -38.9% | -532.4% | -443.8% |